The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

While plans for a Northeast vaccine advisory group remain uncertain, Gilmet says Maine is better positioned than some other ...